Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study of moderate-to-severe asthma

Iribarren, C., Rahmaoui, A., Long, AA., Szefler, SJ., Bradley, MS., Carrigan, G., Eisner, MD., Chen, H., Omachi, TA., Farkouh, ME., & Rothman, K. (2016). Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study of moderate-to-severe asthma. Journal of Allergy and Clinical Immunology, Advance Online Publication. https://doi.org/10.1016/j.jaci.2016.07.038

Abstract

CONCLUSION:

Results from this observational study demonstrated a higher incidence rate of CV/CBV events in the omalizumab versus non-omalizumab cohorts. Differences in asthma severity between cohorts likely contributed to this imbalance, but some increase in risk cannot be excluded (NCT00252135).

CLINICAL IMPLICATIONS:

Current asthma management guidelines should not be affected. However, health professionals should be aware of a possible association of omalizumab and serious cardiovascular/cerebrovascular events.

Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Recent Publications

Article

"Show Me the Energy Costs"
Article

Effectiveness of interventions for the remediation of lead-contaminated soil to prevent or reduce lead exposure-A systematic review
Article

Variation in estimates of heat-related mortality reduction due to tree cover in US cities
Article

Promoting reproducibility and increased collaboration in electric sector capacity expansion models with community benchmarking and intercomparison efforts